Pharma News

GSK presents new data backing shingles vaccine The firm says data show that when Shingrix was given to patients aged 50 years or over at the same time as an unadjuvanted seasonal flu vaccine, both vaccines were well tolerated and the immune response to each vaccine was similar whether it was administered at the same time or separately. On the ... Read More »

Bristol Opdivo discount in kidney cancer changes minds at NICE In July, England’s cost watchdogs weren’t keen on covering Bristol-Myers Squibb’s Opdivo for kidney cancer patients. But the New Jersey drugmaker has said the magic word: discount. Friday, the National Institute for Health and Care Excellence announced a flip-flop on the idea, backing the med for NHS use in previously ... Read More »

Our Culture At VIVAN, our performance-oriented culture and responsible approach are the foundations of our success. We recognize that our business depends on the creativity, innovation, dedication and performance of our Associates. We encourage our Associates to focus on achievements through collaboration, innovation and team work. We support our Associates to take freedom with responsibility, which eventually guides them to ... Read More »

Pharma cos may report low key performance in Q2 FY17   Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, a report said. “We expect the pharmaceutical companies to report subdued performance on sales, EBITDA and PAT front in ... Read More »

Gilead (GILD) Should Buy This Company The investment bank Evercore ISI surveyed 244 biotech industry observers. The primary goal was for them to identify the biotech company they thought mostly likely to be acquired in the next year and who they thought should buy it. Incyte (INCY) was the top pick for an acquisition target, and Gilead Sciences (GILD) won out ... Read More »

Pfizer’s Sutent comes up big in adjuvant kidney cancer trial COPENHAGEN, Denmark–Pfizer’s kidney-cancer fighter Sutent is an aging drug–but it may just have one more label expansion up its sleeve. Among patients with localized kidney cancer that’s been surgically removed–a group considered high-risk for relapse–the med bested placebo in a Phase III study at improving disease-free survival, the New York pharma ... Read More »

2016 Nobel Prize in Physiology or Medicine to Yoshinori Ohsumi The Nobel Prize The Nobel Assembly at Karolinska Institutet has today decided to award the 2016 Nobel Prize in Physiology or Medicine to Yoshinori Ohsumi for his discoveries of mechanisms for autophagy.This year’s Nobel Laureate discovered and elucidated mechanisms underlying autophagy, a fundamental process for degrading and recycling cellular components. ... Read More »

 Marksans Pharma rushes  on USFDA nod for Loratadine Marksans Pharma has moved higher by 12% to Rs 53.55 on the BSE after the company announced that it has got US drug regulator nod for loratadine liquid filed capsules 10 mg. “The US Food & Drug Administration (USFDA) has granted approval for an Abbreviated New Drug Application (ANDA) for Loratadine liquid ... Read More »

FDA Approves First Generic Version of Widely Used Influenza Drug Tamiflu On August 3, 2016, the U.S. Food and Drug Administration approved the first generic version of Tamiflu (oseltamivirphosphate), a widely used medication for the treatment of the flu (influenza A and B) in patients two weeks of age and older who have had flu symptoms for no more than ... Read More »

Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Index for the eighth year running For the eighth consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry of the Dow Jones Sustainability Index (DJSI). This is based on an in-depth analysis of economic, ... Read More »